A systematic review of moral reasons on orphan drug reimbursement

The number of market approvals of orphan medicinal products (OMPs) has been increasing steadily in the last 3 decades. While OMPs can offer a unique chance for patients suffering from rare diseases, they are u...

Source: Orphanet Journal of Rare Diseases - June 30, 2021 Category: Internal Medicine Authors: Bettina M. Zimmermann, Johanna Eichinger and Matthias R. Baumgartner Tags: Review Source Type: research